Key facts
- Immunorock’s last known valuation is $8.3M (Feb 2026).
- It has raised $2.6M; the latest was Later Stage VC ($1.5M) in Feb 2026.
- Notable investors include J-Startup, Osaka University Venture Capital, Kobe Shinkin Bank, KNC Laboratories, Kobe University — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Immunorock
- ·The full record, as it builds
Funding rounds
No funding rounds for Immunorock are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Immunorock
Developer of a biopharmaceutical platform designed to accelerate the clinical translation of academic discoveries into immunotherapies. The company's platform offers an oral cancer vaccine using genetically engineered bifidobacteria that deliver full-length tumor antigens to the gut immune system, enabling cancer patients access to a novel, non-invasive immunotherapy that induces strong cytotoxic T cell responses.
- Sector
- Healthcare
- HQ
- Kobe, Japan
- Founded
- 2021
- Website
- immunorock.com/
- Ownership
- Privately Held (backing)
Immunorock doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immunorock shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immunorock in its N-PORT filings yet. We sweep new filings monthly.